These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 22680408)

  • 21. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.
    Koel-Simmelink MJ; Vennegoor A; Killestein J; Blankenstein MA; Norgren N; Korth C; Teunissen CE
    J Immunol Methods; 2014 Jan; 402(1-2):43-9. PubMed ID: 24275679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoneurofilament heavy chain and N-glycomics from the cerebrospinal fluid in amyotrophic lateral sclerosis.
    Gonçalves M; Tillack L; de Carvalho M; Pinto S; Conradt HS; Costa J
    Clin Chim Acta; 2015 Jan; 438():342-9. PubMed ID: 25261856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Kawajiri M; Mogi M; Higaki N; Tateishi T; Ohyagi Y; Horiuchi M; Miki T; Kira JI
    Acta Neurol Scand; 2009 May; 119(5):341-4. PubMed ID: 18798831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype.
    Zetterberg H; Jacobsson J; Rosengren L; Blennow K; Andersen PM
    Eur J Neurol; 2007 Dec; 14(12):1329-33. PubMed ID: 17903209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.
    Kojima Y; Kasai T; Noto YI; Ohmichi T; Tatebe H; Kitaoji T; Tsuji Y; Kitani-Morii F; Shinomoto M; Allsop D; Teramukai S; Mizuno T; Tokuda T
    PLoS One; 2021; 16(11):e0260323. PubMed ID: 34843548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis.
    Boylan KB; Glass JD; Crook JE; Yang C; Thomas CS; Desaro P; Johnston A; Overstreet K; Kelly C; Polak M; Shaw G
    J Neurol Neurosurg Psychiatry; 2013 Apr; 84(4):467-72. PubMed ID: 23117489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.
    Zheng Y; Gao L; Wang D; Zang D
    Acta Neurol Scand; 2017 Aug; 136(2):145-150. PubMed ID: 27804118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
    Xu Z; Henderson RD; David M; McCombe PA
    PLoS One; 2016; 11(10):e0164625. PubMed ID: 27732645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF.
    Rosengren LE; Karlsson JE; Karlsson JO; Persson LI; Wikkelsø C
    J Neurochem; 1996 Nov; 67(5):2013-8. PubMed ID: 8863508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis.
    Paladino P; Valentino F; Piccoli T; Piccoli F; La Bella V
    Eur J Neurol; 2009 Feb; 16(2):257-61. PubMed ID: 19138331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid levels of chromogranin A and phosphorylated neurofilament heavy chain are elevated in amyotrophic lateral sclerosis.
    Kaiserova M; Grambalova Z; Otruba P; Stejskal D; Prikrylova Vranova H; Mares J; Mensikova K; Kanovsky P
    Acta Neurol Scand; 2017 Oct; 136(4):360-364. PubMed ID: 28185258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
    Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M
    Neurology; 2018 Jan; 90(1):e22-e30. PubMed ID: 29212830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis.
    Puentes F; Topping J; Kuhle J; van der Star BJ; Douiri A; Giovannoni G; Baker D; Amor S; Malaspina A
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):274-8. PubMed ID: 24078718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X
    Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    De Schaepdryver M; Jeromin A; Gille B; Claeys KG; Herbst V; Brix B; Van Damme P; Poesen K
    J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):367-373. PubMed ID: 29054919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
    Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion.
    Benatar M; Wuu J; Andersen PM; Lombardi V; Malaspina A
    Ann Neurol; 2018 Jul; 84(1):130-139. PubMed ID: 30014505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurofilament heavy subunit in cerebrospinal fluid: a biomarker of amyotrophic lateral sclerosis?
    Mendonça DM; Martins SC; Higashi R; Muscara MN; Neto VM; Chimelli L; Martinez AM
    Amyotroph Lateral Scler; 2011 Mar; 12(2):144-7. PubMed ID: 21198418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes.
    Lindborg SR; Goyal NA; Katz J; Burford M; Li J; Kaspi H; Abramov N; Boulanger B; Berry JD; Nicholson K; Mozaffar T; Miller R; Jenkins L; Baloh RH; Lewis R; Staff NP; Owegi MA; Dagher B; Blondheim-Shraga NR; Gothelf Y; Levy YS; Kern R; Aricha R; Windebank AJ; Bowser R; Brown RH; Cudkowicz ME
    Muscle Nerve; 2024 Jun; 69(6):719-729. PubMed ID: 38593477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis.
    Wilke C; Deuschle C; Rattay TW; Maetzler W; Synofzik M
    Neurobiol Aging; 2015 Feb; 36(2):1072-4. PubMed ID: 25453560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.